{"id":"placebo-to-sugammadex","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sugammadex works by forming a tight 1:1 complex with rocuronium (and other steroidal neuromuscular blockers), effectively removing the active drug from the neuromuscular junction and shifting the equilibrium to favor reversal of blockade. This allows rapid restoration of neuromuscular function without the need for acetylcholinesterase inhibitors. The complex is then renally eliminated.","oneSentence":"Sugammadex is a selective relaxant binding agent that encapsulates rocuronium and other neuromuscular blocking agents, rapidly reversing neuromuscular blockade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:58.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery"}]},"trialDetails":[{"nctId":"NCT05661409","phase":"PHASE4","title":"Sugammadex as Rescue Therapy","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-07-21","conditions":"Neuromuscular Blockade","enrollment":46},{"nctId":"NCT05558969","phase":"NA","title":"The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex","status":"COMPLETED","sponsor":"Eskisehir Osmangazi University","startDate":"2022-09-28","conditions":"Magnesium Sulfate, Pregnancy; Pre-Eclampsia, Neuromuscular Blockade","enrollment":30},{"nctId":"NCT06623370","phase":"PHASE4","title":"The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group","status":"COMPLETED","sponsor":"Konya City Hospital","startDate":"2024-10-01","conditions":"Sugammadex Reversal Time, Muscle Weakness","enrollment":80},{"nctId":"NCT02728726","phase":"PHASE4","title":"Sugammadex vs Placebo to Prevent Residual Neuromuscular Block","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-06","conditions":"General Surgery","enrollment":260},{"nctId":"NCT01937247","phase":"PHASE2, PHASE3","title":"Redesigned Process in the Operating Room","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2018-05-18","conditions":"Non-operative Time, General Surgery, Above 18 Years of Age","enrollment":120},{"nctId":"NCT03196167","phase":"PHASE4","title":"Sugammadex and Decreased Time to Extubation","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-05-13","conditions":"Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery","enrollment":90},{"nctId":"NCT01422304","phase":"PHASE3","title":"Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-12","conditions":"Neuromuscular Blockade, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee","enrollment":1198},{"nctId":"NCT00552617","phase":"PHASE2","title":"A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09-20","conditions":"Anesthesia, General","enrollment":100},{"nctId":"NCT03226080","phase":"PHASE4","title":"GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture","status":"WITHDRAWN","sponsor":"Loyola University","startDate":"2017-07-19","conditions":"Hip Fractures, Anesthesia, Spinal, Anesthesia, General","enrollment":""},{"nctId":"NCT02028065","phase":"PHASE1","title":"A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01-03","conditions":"Hypersensitivity, Anaphylaxis","enrollment":382},{"nctId":"NCT03519854","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-12-01","conditions":"Neuromuscular Blockade","enrollment":99},{"nctId":"NCT03369782","phase":"PHASE4","title":"Effect of NMBA on Surgical Conditions in THR","status":"WITHDRAWN","sponsor":"Algemeen Ziekenhuis Maria Middelares","startDate":"2017-12-15","conditions":"Surgery, Postoperative Pain","enrollment":""},{"nctId":"NCT00591409","phase":"PHASE2","title":"A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-03","conditions":"Anesthesia, General","enrollment":100},{"nctId":"NCT00535743","phase":"PHASE2","title":"Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-03-04","conditions":"Anesthesia, General","enrollment":174},{"nctId":"NCT00988065","phase":"PHASE1","title":"Sugammadex Hypersensitivity Study (Study P06042)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-06","conditions":"Hypersensitivity","enrollment":448},{"nctId":"NCT00421148","phase":"PHASE3","title":"Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-05-30","conditions":"Anesthesia","enrollment":94},{"nctId":"NCT03131375","phase":"PHASE2, PHASE3","title":"Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia","status":"COMPLETED","sponsor":"Athens General Children's Hospital \"Pan. & Aglaia Kyriakou\"","startDate":"2017-05-01","conditions":"Emergence Delirium, Extubation Time, Heart Rate","enrollment":60},{"nctId":"NCT00379613","phase":"PHASE2","title":"Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-11-07","conditions":"Anesthesia, General","enrollment":45},{"nctId":"NCT02510157","phase":"NA","title":"Effect of Dexamethasone on the Action of Sugammadex","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2015-05","conditions":"Neuromuscular Blockade","enrollment":44},{"nctId":"NCT02769325","phase":"PHASE4","title":"Atropine in Laparoscopic Gynaecological Surgery","status":"UNKNOWN","sponsor":"Clinica Santa Maria","startDate":"2016-05","conditions":"Laparoscopic Surgery, Gynecology","enrollment":150},{"nctId":"NCT02079337","phase":"PHASE4","title":"Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery","status":"COMPLETED","sponsor":"Herlev Hospital","startDate":"2013-11","conditions":"Surgical Conditions, Rating Scales, Laparoscopy","enrollment":14},{"nctId":"NCT01440933","phase":"PHASE2","title":"Efficacy of Sugammadex in Magnesium Pretreated Patients","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2011-09","conditions":"Neuromuscular Block","enrollment":32},{"nctId":"NCT01424488","phase":"PHASE4","title":"Sugammadex Efficacy and Safety for Reversal of Pipecuronium-induced Neuromuscular Blockade","status":"UNKNOWN","sponsor":"Central Clinical Hospital #1 of LLC Russian Railways","startDate":"2011-09","conditions":"Adult Subjects Undergoing Abdominal Surgery Under General Anesthesia","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to sugammadex","genericName":"Placebo to sugammadex","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sugammadex is a selective relaxant binding agent that encapsulates rocuronium and other neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}